A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ...

Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive ...

The mystery of how cancers build up resistance mechanisms and evade the treatments that should have destroyed them is a hugely pressing question. Overcoming cancer treatment resistance—a phenomenon ...